These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25424771)

  • 1. Treating Immune-tolerant Hepatitis B.
    Tseng TC; Kao JH
    J Viral Hepat; 2015 Feb; 22(2):77-84. PubMed ID: 25424771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1762-9. PubMed ID: 23808759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
    Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
    Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
    Liaw YF
    Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.
    Lau GK
    Liver Int; 2010 Apr; 30(4):512-20. PubMed ID: 20102511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
    Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.
    Zheng Q; Zhu YY; Chen J; Liu YR; You J; Dong J; Zeng DW; Gao LY; Chen LH; Jiang JJ
    J Viral Hepat; 2014 Dec; 21(12):909-16. PubMed ID: 24888640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
    Singh AK; Sharma MK; Hissar SS; Gupta E; Sarin SK
    J Viral Hepat; 2014 Jun; 21(6):439-46. PubMed ID: 24750522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of chronic hepatitis B in children: an unresolved issue.
    Della Corte C; Nobili V; Comparcola D; Cainelli F; Vento S
    J Gastroenterol Hepatol; 2014 May; 29(5):912-9. PubMed ID: 24863185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.